| Literature DB >> 30753871 |
Melanie H Wong1, Alexandra B Samal2, Mike Lee1, Jiri Vlach2, Nikolai Novikov1, Anita Niedziela-Majka1, Joy Y Feng1, Dmitry O Koltun1, Katherine M Brendza1, Hyock Joo Kwon1, Brian E Schultz1, Roman Sakowicz1, Jamil S Saad3, Giuseppe A Papalia4.
Abstract
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine protein kinase that transmits calcium signals in various cellular processes. CaMKII is activated by calcium-bound calmodulin (Ca2+/CaM) through a direct binding mechanism involving a regulatory C-terminal α-helix in CaMKII. The Ca2+/CaM binding triggers transphosphorylation of critical threonine residues proximal to the CaM-binding site leading to the autoactivated state of CaMKII. The demonstration of its critical roles in pathophysiological processes has elevated CaMKII to a key target in the management of numerous diseases. The molecule KN-93 is the most widely used inhibitor for studying the cellular and in vivo functions of CaMKII. It is widely believed that KN-93 binds directly to CaMKII, thus preventing kinase activation by competing with Ca2+/CaM. Herein, we employed surface plasmon resonance, NMR, and isothermal titration calorimetry to characterize this presumed interaction. Our results revealed that KN-93 binds directly to Ca2+/CaM and not to CaMKII. This binding would disrupt the ability of Ca2+/CaM to interact with CaMKII, effectively inhibiting CaMKII activation. Our findings also indicated that KN-93 can specifically compete with a CaMKIIδ-derived peptide for binding to Ca2+/CaM. As indicated by the surface plasmon resonance and isothermal titration calorimetry data, apparently at least two KN-93 molecules can bind to Ca2+/CaM. Our findings provide new insight into how in vitro and in vivo data obtained with KN-93 should be interpreted. They further suggest that other Ca2+/CaM-dependent, non-CaMKII activities should be considered in KN-93-based mechanism-of-action studies and drug discovery efforts.Entities:
Keywords: CaMKII; KN-92; KN-93; calmidazolium; calmodulin
Year: 2019 PMID: 30753871 DOI: 10.1016/j.jmb.2019.02.001
Source DB: PubMed Journal: J Mol Biol ISSN: 0022-2836 Impact factor: 5.469